A phase II clinical study of suramin in combination with mitomycin C in patients with non small cell lung cancer

Bernardo Leon Rapoport, Geoffrey Falkson, Stephen Maxted Ansell, Barend Petrus Lotz, Magriet de Wet

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Fifteen patients with advanced non small cell lung cancer (NSCLC) were entered into a study of suramin given as a 4 h infusion of 350 mg/m2 per day for 5 days, followed by 350 mg/m2 weekly from day 14, plus mitomycin C (MMC) 12 mg/m2 given every 5 weeks starting on day 14. No responses were seen in the 15 patients treated with suramin and MMC. One patient experienced lethal toxic epidermonecrolysis. Other toxicities were mild and consisted of a maculopapular skin rash in 5 patients, temporary sensory peripheral neuropathy in 4 patients and proteinuria in 2 patients. Mild nausea and vomiting occurred in 3, mild leucopenia or thrombocytopenia in 2 and moderate infection in 3 patients. The median time to treatment failure was 28 days. The median survival time was 155 days. Suramin in combination with MMC has acceptable toxicity but showed no therapeutic activity in patients with NSCLC in this trial.

Original languageEnglish (US)
Pages (from-to)323-328
Number of pages6
JournalLung Cancer
Volume7
Issue number5
DOIs
StatePublished - 1991
Externally publishedYes

Fingerprint

Suramin
Mitomycin
Non-Small Cell Lung Carcinoma
Clinical Studies
Poisons
Leukopenia
Peripheral Nervous System Diseases
Exanthema
Treatment Failure
Proteinuria
Nausea
Vomiting
Survival

Keywords

  • Mitomycin-C
  • Non Small Cell Lung Cancer
  • Suramin

ASJC Scopus subject areas

  • Oncology

Cite this

A phase II clinical study of suramin in combination with mitomycin C in patients with non small cell lung cancer. / Rapoport, Bernardo Leon; Falkson, Geoffrey; Ansell, Stephen Maxted; Lotz, Barend Petrus; de Wet, Magriet.

In: Lung Cancer, Vol. 7, No. 5, 1991, p. 323-328.

Research output: Contribution to journalArticle

Rapoport, Bernardo Leon ; Falkson, Geoffrey ; Ansell, Stephen Maxted ; Lotz, Barend Petrus ; de Wet, Magriet. / A phase II clinical study of suramin in combination with mitomycin C in patients with non small cell lung cancer. In: Lung Cancer. 1991 ; Vol. 7, No. 5. pp. 323-328.
@article{2034215047f8475ba1b6a5be17ebce38,
title = "A phase II clinical study of suramin in combination with mitomycin C in patients with non small cell lung cancer",
abstract = "Fifteen patients with advanced non small cell lung cancer (NSCLC) were entered into a study of suramin given as a 4 h infusion of 350 mg/m2 per day for 5 days, followed by 350 mg/m2 weekly from day 14, plus mitomycin C (MMC) 12 mg/m2 given every 5 weeks starting on day 14. No responses were seen in the 15 patients treated with suramin and MMC. One patient experienced lethal toxic epidermonecrolysis. Other toxicities were mild and consisted of a maculopapular skin rash in 5 patients, temporary sensory peripheral neuropathy in 4 patients and proteinuria in 2 patients. Mild nausea and vomiting occurred in 3, mild leucopenia or thrombocytopenia in 2 and moderate infection in 3 patients. The median time to treatment failure was 28 days. The median survival time was 155 days. Suramin in combination with MMC has acceptable toxicity but showed no therapeutic activity in patients with NSCLC in this trial.",
keywords = "Mitomycin-C, Non Small Cell Lung Cancer, Suramin",
author = "Rapoport, {Bernardo Leon} and Geoffrey Falkson and Ansell, {Stephen Maxted} and Lotz, {Barend Petrus} and {de Wet}, Magriet",
year = "1991",
doi = "10.1016/0169-5002(91)90029-6",
language = "English (US)",
volume = "7",
pages = "323--328",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "5",

}

TY - JOUR

T1 - A phase II clinical study of suramin in combination with mitomycin C in patients with non small cell lung cancer

AU - Rapoport, Bernardo Leon

AU - Falkson, Geoffrey

AU - Ansell, Stephen Maxted

AU - Lotz, Barend Petrus

AU - de Wet, Magriet

PY - 1991

Y1 - 1991

N2 - Fifteen patients with advanced non small cell lung cancer (NSCLC) were entered into a study of suramin given as a 4 h infusion of 350 mg/m2 per day for 5 days, followed by 350 mg/m2 weekly from day 14, plus mitomycin C (MMC) 12 mg/m2 given every 5 weeks starting on day 14. No responses were seen in the 15 patients treated with suramin and MMC. One patient experienced lethal toxic epidermonecrolysis. Other toxicities were mild and consisted of a maculopapular skin rash in 5 patients, temporary sensory peripheral neuropathy in 4 patients and proteinuria in 2 patients. Mild nausea and vomiting occurred in 3, mild leucopenia or thrombocytopenia in 2 and moderate infection in 3 patients. The median time to treatment failure was 28 days. The median survival time was 155 days. Suramin in combination with MMC has acceptable toxicity but showed no therapeutic activity in patients with NSCLC in this trial.

AB - Fifteen patients with advanced non small cell lung cancer (NSCLC) were entered into a study of suramin given as a 4 h infusion of 350 mg/m2 per day for 5 days, followed by 350 mg/m2 weekly from day 14, plus mitomycin C (MMC) 12 mg/m2 given every 5 weeks starting on day 14. No responses were seen in the 15 patients treated with suramin and MMC. One patient experienced lethal toxic epidermonecrolysis. Other toxicities were mild and consisted of a maculopapular skin rash in 5 patients, temporary sensory peripheral neuropathy in 4 patients and proteinuria in 2 patients. Mild nausea and vomiting occurred in 3, mild leucopenia or thrombocytopenia in 2 and moderate infection in 3 patients. The median time to treatment failure was 28 days. The median survival time was 155 days. Suramin in combination with MMC has acceptable toxicity but showed no therapeutic activity in patients with NSCLC in this trial.

KW - Mitomycin-C

KW - Non Small Cell Lung Cancer

KW - Suramin

UR - http://www.scopus.com/inward/record.url?scp=0025988745&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025988745&partnerID=8YFLogxK

U2 - 10.1016/0169-5002(91)90029-6

DO - 10.1016/0169-5002(91)90029-6

M3 - Article

VL - 7

SP - 323

EP - 328

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 5

ER -